Chairman of the Board
Timothy Wollaeger has more than 30 years’ experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling Ventures as a Managing Director in 2002, and opened the firm’s San Diego office. Mr. Wollaeger serves on the board of directors for several Sanderling portfolio companies, including Asteres, Sotera Wireless, CalciMedica and REN. He is Chairman of the Board of Directors for Chimerix and is Chairman and Chief Executive Officer of Harkness Pharmaceuticals.
Prior to joining Sanderling in 1994, Mr. Wollaeger founded the venture capital firm Kingsbury Capital Partners. At Kingsbury, seed and early stage investing was combined with active management and portfolio companies included Aurora Biosciences, Amylin Pharmaceuticals (NASDAQ: AMLN), Senomyx (NASDAQ: SNMX), and Althea Technologies. He was named E&Y San Diego’s Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001.
Prior to Kingsbury Capital Partners, Mr. Wollaeger helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the board of directors until 1994. In 1986, Mr. Wollaeger became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found Pyxis, Biosite, Amlin Pharmaceuticals (NASDAQ: AMLN) and Vical (NASDAQ: VICL). All four of these companies became public. Pyxis was acquired by Cardinal Health in 1996 for $1 billion and Biosite was acquired by Inverness Medical Innovations Inc. in 2007 for $1.7 billion.
In 1983, Mr. Wollaeger joined Hybritech, Inc., San Diego’s first biotechnology company, as Vice President and Chief Financial Officer until Hybritech was acquired by Eli Lilly & Co. (NYSE: LLY) in 1986.He began his life science career at Baxter International where he was Manager of Operations Analysis. His last position was Vice President and General Manager of the Company’s operations in Mexico.
Mr. Wollaeger earned a bachelor’s degree in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned a master’s degree in business administration from The Stanford Graduate School of Business in 1971.
Tom Watlington, whose experience in the medical device industry spans 28 years, joined Sotera Wireless as Chief Executive Officer in February 2006. During that year he served a dual role as President of Naviscan Pet Systems, a medical imaging company, before transitioning to a full-time position with Sotera Wireless in January 2007.For ten years prior to joining Sotera Wireless, Mr. Watlington served as Senior Vice President of Commercial Operations and later as Executive Vice President and Chief Operating Officer of Biosite Incorporated, a leader in the field of medical diagnostics. In addition, he spent fourteen years at Boehringer Mannheim Corporation in various sales, marketing and strategic roles, including Vice President of Marketing for the Diabetes Care division.
Mr. Watlington previously served on the board of Home Diagnostics, Inc., a public company in the field of diabetes monitoring that was acquired in June 2010 by Nipro Diagnostics. He received a bachelor of science degree from the University of Maryland.
Kenneth Buechler, Ph.D.
Kenneth Buechler, Ph.D., was most recently President, Chief Scientific Officer and co-founder of Biosite Incorporated. Dr. Buechler is a co-inventor of certain Biosite proprietary technologies, including the Biosite® Drugs of Abuse Panel and the Biosite Meter Plus platform. From 1988 to 1994, Dr. Buechler was Biosite’s Director of Chemistry. Prior to forming Biosite, he was a senior research scientist for the Diagnostics Research and Development Group at Hybritech Incorporated in San Diego. As a Senior Research Scientist, he was responsible for new product development and was the transfer project leader for ICON® QSR CK-MB, a cardiac marker assay. In addition, he was responsible for the design and synthesis of reagents for use in the first rapid, visual pregnancy test, the ICON® hCG test.
Dr. Buechler received his Ph.D. in biochemistry and his bachelor’s degree in chemistry from Indiana University. He is a member of the American Chemical Society, the Biochemical Society, the International Federation of Clinical Chemistry and Laboratory Medicine and the American Association of Clinical Chemists.
Matthew Buten joined Foresite Capital as they closed their first dedicated fund in January 2012, Foresite Capital I and is currently Managing Director. Foresite Capital is a growth equity fund dedicated to healthcare investing. Foresite is now investing through its 2nd dedicated fund, Foresite Capital II.
Matt has more than 15 years experience as a healthcare investor and 15 years experience in investment banking advising and structuring deals for both small and large capitalization companies. Most recently, he was a healthcare portfolio manager at Catapult/Millennium Partners focused on US healthcare services, medical technology, life science tools, big pharmaceutical, and specialty pharmaceutical. While at Millennium, he managed $400-600 million of combined long/short market neutral capital. Prior to joining Millennium in mid-2007, he was co-founder and co-manager of Sapphire Capital, where he focused on medical technology, diagnostics, life science tools suppliers, diagnostic services, and healthcare information technology. From 2000-2005 he was an equity analyst for Argus Partners and its predecessor. Argus was a $1 billion healthcare fund and Matt was focused on medical technology. Prior to Argus, he was Managing Director and Head of Healthcare Investment Banking for Needham and Company. While at Needham, he also sourced healthcare venture capital opportunities for their venture capital fund, Needham Capital Partners. Prior to joining Needham in 1996, he worked at Smith Barney as a Director in the Investment Banking division. He started there in 1985, as an investment banking Associate focused on mergers and acquisitions, equity and debt financings and spin-offs.
Matt received his BS from the Wharton School in 1983 with a concentration in corporate finance.
Dr. Tony DeMaria, M.D.
Anthony N. DeMaria received his M.D. from the New Jersey College of Medicine in 1968. He did his medical residency at the United States Public Health Service Hospital inStaten Island,New York. He completed his cardiology fellowship training at theUniversityofCalifornia,Davisand upon completion joined the faculty at UC Davis. In 1981, he accepted the position as Chief of Cardiology at theUniversityofKentuckyinLexington,Kentucky. He remained in that position until 1992 when he accepted the position as Professor of Medicine and Chief, Division of Cardiology at theUniversityofCalifornia,San Diego. In 2004 he founded theUCSDSulpizioFamilyCardiovascularCenter. His field of specialization is cardiac imaging techniques, particularly echocardiography (ultrasound of the heart).
Dr. DeMaria is a Diplomat in the American Board of Internal Medicine and is board certified by the Subspecialty Board in Cardiovascular Disease. He is Past President of theAmericanCollegeof Cardiology and Past President of the American Society of Echocardiography. He has served as a member of the Subspecialty Board on Cardiovascular Disease of the American Board of Internal Medicine and Chair of the Diagnostic Radiology Study Section of the National Institutes of Health. He holds memberships in numerous professional organizations, including the American Heart Association, the American Federation for Clinical Research and the Association of University Cardiologists.
Dr. DeMaria is currently the Editor-in-Chief of the Journal of the American College of Cardiology and has served as an editorial consultant and member of various other editorial boards. He has authored or co-authored over 530 articles for medical journals. Dr. DeMaria is listed in the Best Doctors in America and by Good Housekeeping as Best Heart Doctors in America.
Mr. Kandaswamy joined Intel Capital in 1999 and works closely with Intel’s Digital Health Group and the Corporate Technology Groups’ Communications Technology Lab and Personal Health team. Prior to Intel Capital, Bobby was a Senior Manager driving new business initiatives at Cardinal Health, a global leader in medical and surgical products (NYSE: CAH). Before that Bobby worked at Baxter Healthcare (NYSE: BAX) in business development and product development roles.
Bobby is currently a board observer at Grid Net, Life Masters, PacketMotion and Sotera Wireless. He has also invested in and managed exits at FutureSoft (acquired by Flextronics), IP Infusion (acquired by Access) and NetScaler (acquired by Citrix). Bobby has a master’s degree in business administration from J.L. Kellogg Graduate School of Management and a master of science degree in industrial engineering from Northern Illinois University.
Dr. Walter Lim, M.D.
Dr Walter Lim is responsible for EDBI’s investment activities in digital health, with a focus on growth-stage opportunities. At EDBI, he has led investments in Sotera Wireless, Gobalto and PatientSafe Solutions. Prior to EDBI, Walter served as Practice Lead at Ministry of Health Holdings Singapore, where he developed Singapore’s national e-Health investment strategy and was instrumental in raising funding for the first phase of Singapore’s national EHR program. Outside of digital health, Walter covers investment opportunities in the broader healthcare space including medical devices, healthcare services, and has been closely involved in expansion of EDBI’s investor network in China. Walter began his career in internal medicine and has practiced in a broad range of in-patient and high-acuity settings. Walter holds an MBBS from the National University of Singapore and an MBA with distinction from INSEAD.
Dr. Loh leads EDBI’s West America investment activities in biomedical sciences, clean technology and internet/digital media and is based in Silicon Valley, California. He joined Bio*One Capital, EDBI’s dedicated healthcare investment arm in 2007 and was responsible for investment in the medtech sector. Dr. Loh currently serves on the boards of Sotera Wireless, Amaranth Medical and Contour Energy and received his mechanical and bio-engineering training at A*STAR, Nanyang Technological University, University of Southampton and Imperial College London. Prior to that, he spearheaded an engineering team developing autonomous machines in a robotic start-up (subsequently acquired) and held multiple patents for diagnostic and bio-artificial organ applications.
Charles A. (Chuck) Sted
From 2004 to his retirement in 2013, Chuck was president and CEO of Hawai‘i Pacific Health, a $1 billion annual net revenue, clinically integrated system of four hospitals, 49 clinics, 350 employed and 700 active independent medical staff. He was CFO from 1998 and negotiated the merger of three health systems to form HPH. The organization is nationally recognized for its leading use of the EPIC electronic medical record system to transform health care delivery. Chuck served on the board of HPH and each of its 14 non-profit and for profit subsidiaries.
From 1992 to 1998 Chuck served as CFO of Bank of America Hawai‘i. He was with Ernst & Young from 1974-1992 and became a partner in 1985.
He serves as a director and treasurer of the Hawai‘i Cancer Consortium. He has served as Chairman of the Board of Trustees of Hawai‘i Pacific University, Chairman of the Hawai‘i Business Roundtable and in numerous other chair and leadership roles in Hawai‘i organizations. “
Bert Zimmerli, executive vice president and chief financial officer, joined Intermountain Healthcare in 2003. He is responsible for the direction and oversight of all Intermountain Healthcare financial operations. He also oversees Intermountain’s insurance/health plans operations, SelectHealth, as well as Intermountain’s Information Systems operations. More recently, he has led the planning and provided leadership for Intermountain’s Business Development and Outreach Services. Bert chairs the board of directors of Amerinet and serves on the executive board of the Salt Lake Chamber of Commerce.
Prior to joining Intermountain Healthcare, Bert was the executive vice president and chief financial officer of the Methodist Hospital System in Houston, Texas. Prior to that, he served in numerous capacities with Memorial Hermann Healthcare System in Houston, including senior vice president, chief financial officer and was president of several of its smaller subsidiaries. He also was a partner in Ernst & Young’s Houston office, where he spent 16 years, specializing in healthcare.
Bert received a bachelor’s degree in accounting and a master’s degree in business administration, both from the University of Wisconsin. He is a Certified Public Accountant and received the Elijah Watt Sells Award for receiving the second-highest score in the nation when he took the CPA exam.